Monograph
N02AF02 - Nalbuphine |
Propably not porphyrinogenic |
PNP |
Side effects
Common adverse reactions of nalbuphine that can be confused with an acute porphyric attack are nausea and vomiting. These side effects may potentially be porphyrinogenic if leading to a decrease in carbohydrate intake.
Rationale
Nalbuphine is not suspected to be an inducer or a mechanism-based inhibitor of CYP enzymes, and is not observed to alter the metabolism of other CYP metabolized drugs.
Chemical description
Opioid, epoxymorphinan structure
Therapeutic characteristics
Nalbuphine is an opioid used in the treatment of acute moderate to severe pain.
It is administered as an intravenous injection.
Metabolism and pharmacokinetics
Nalbuphine is metabolized in the liver. It undergoes hydroxylation by CYP450 enzymes and glucuronidation by UGTs (Wang 2014). It is excreted in the urine and feces as unchanged drug and glucuronide conjugates. There is no information regarding the specific enzymes participating in the metabolism, or pharmacokinetic drug interactions (FASS).
References
| # | Citation details | PMID |
|---|---|---|
| * | Scientific articles | |
| 1. | J, Hsiong, C.H., et al. New finding of nalbuphine metabolites in men: NMR spectroscopy and UPLC–MS/MS spectrometry assays in a pilot human study. Metabolomics (2014) 10:709–718.
Wang H. |
|
| * | Other sources | |
| 2. | Swedish National Formulary. FASS. (Nalpain). www.fass.se (product leaflet)
|
|
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
United Kingdom
Poland© NAPOS 2024